CTMX - CytomX Therapeutics, Inc.
6.72 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 7.12 |
| Open | 7.07 |
| Bid | 6.71 x 2900 |
| Ask | 6.73 x 900 |
| Day's Range | 6.69 - 7.33 |
| 52 Week Range | 6.64 - 19.75 |
| Volume | 362,209 |
| Avg. Volume | 376,555 |
| Market Cap | 305.152M |
| Beta (3Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.20 |
| Earnings Date | Aug 7, 2019 - Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.00 |
- GlobeNewswire
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- GlobeNewswire
CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer
CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced the appointment of Amy C. Peterson, M.D., as executive vice president and chief development officer. “Amy brings to CytomX extensive clinical development and leadership skills along with a track record of implementing successful oncology clinical strategies through product registration which will benefit us enormously as we continue to advance our novel and differentiated portfolio of Probody therapeutics,” said Sean McCarthy, D. Phil., president, chief executive officer and chairman of CytomX.
- Simply Wall St.
Will CytomX Therapeutics (NASDAQ:CTMX) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
CytomX Therapeutics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- Simply Wall St.
Did CytomX Therapeutics, Inc. (NASDAQ:CTMX) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Thomson Reuters StreetEvents
Edited Transcript of CTMX earnings conference call or presentation 7-Aug-19 9:00pm GMT
Q2 2019 CytomX Therapeutics Inc Earnings Call
Motley FoolCytomX Therapeutics, Inc. (CTMX) Q2 2019 Earnings Call Transcript
CTMX earnings call for the period ending June 30, 2019.
- Zacks
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- GlobeNewswire
CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- Zacks
Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
CytomX Therapeutics to Announce Second Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., July 30, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
- Benzinga
Analyst: CytomX Therapeutics Validated By AbbVie Decision
AbbVie Inc (NYSE: ABBV ) has selected a second target under an existing collaboration with CytomX Therapeutics Inc (NASDAQ: CTMX ) for probody technology. This development is “incrementally positive” for ...
- GlobeNewswire
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates (“PDC”). The target selection triggers a $10 million payment to CytomX from AbbVie. This is the second of two research targets available to AbbVie under the agreement.
- Simply Wall St.
Did You Manage To Avoid CytomX Therapeutics's (NASDAQ:CTMX) Painful 51% Share Price Drop?
CytomX Therapeutics, Inc. (NASDAQ:CTMX) shareholders should be happy to see the share price up 13% in the last month...
- Insider Monkey
Here’s What Hedge Funds Think About CytomX Therapeutics, Inc. (CTMX)
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 8 months is one of those periods, as the Russell 2000 […]
- GlobeNewswire
CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif.,.
- Thomson Reuters StreetEvents
Edited Transcript of CTMX earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 CytomX Therapeutics Inc Earnings Call
- GlobeNewswire
CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
Motley FoolCytomX Therapeutics, Inc. (CTMX) Q1 2019 Earnings Call Transcript
CTMX earnings call for the period ending March 31, 2019.
- Insider Monkey
Were Hedge Funds Right About Dumping CytomX Therapeutics, Inc. (CTMX)?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Zacks
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
CytomX Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 31 cents. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by ...
- GlobeNewswire
CytomX Therapeutics Announces First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
